Galapagos and e-therapeutics are partnering to investigate mechanisms involved in idiopathic pulmonary fibrosis (IPF) and other fibrotic…
Articles by Inês Martins, PhD
The Committee for Medicinal Products for Human Use (CHMP), an arm of the …
Ofev (nintedanib), an oral medication by Boehringer Ingelheim, is now approved to treat people with progressive fibrosing interstitial lung…
Algernon Pharmaceuticals received the first ethics approval for its Phase 2 clinical trial in Australia evaluating its repurposed compound NP-120…
Veracyte has acquired the rights to a gene signature that may serve as a tool, based on a simple blood…
People with idiopathic pulmonary fibrosis (IPF) have shorter survival times after an acute exacerbation than do those with other interstitial…
In very rare cases, a tuberculosis infection in people with idiopathic pulmonary fibrosis (IPF) and lung cancer may…
Researchers at Johns Hopkins University have identified a new gene that, when mutated, increases the risk for pulmonary fibrosis and…
A collaborative research effort identified new pathways involved in fibrosis using a software tool known as “Regeneration Intelligence,” which evaluated perturbations in several…
Patients with idiopathic pulmonary fibrosis (IPF) may benefit from Esbriet (pirfenidone) treatment regardless of their disease stage and baseline lung…